Madrigal Pharmaceuticals
MDGL
188 hedge funds and large institutions have $3.86B invested in Madrigal Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 80 funds opening new positions, 54 increasing their positions, 38 reducing their positions, and 23 closing their positions.
405% more capital invested
Capital invested by funds: $763M → $3.86B (+$3.09B)
350% more funds holding in top 10
Funds holding in top 10: 2 → 9 (+7)
248% more first-time investments, than exits
New positions opened: 80 | Existing positions closed: 23
42% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 38
39% more funds holding
Funds holding: 135 → 188 (+53)
9.21% more ownership
Funds ownership: 68.67% → 77.88% (+9.2%)
31% less call options, than puts
Call options by funds: $379M | Put options by funds: $546M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$42.1M |
| 2 |
PA
Perceptive Advisors
New York
|
+$39.2M |
| 3 |
State Street
Boston,
Massachusetts
|
+$28.8M |
| 4 |
TCM
TCG Crossover Management
Palo Alto,
California
|
+$25.2M |
| 5 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$17.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$101M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$15.6M |
| 3 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$6.21M |
| 4 |
Jennison Associates
New York
|
-$5.33M |
| 5 |
SSA
Schonfeld Strategic Advisors
New York
|
-$5.29M |
MDGL Hedge Fund Activity: Q4 2022 in Review
188 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Madrigal Pharmaceuticals (MDGL) for Q4 2022, worth a combined $3.86B — up 405% from $763M a quarter earlier.
Buyers outnumbered sellers: 80 funds opened new MDGL positions and 23 closed out — a net gain of 57 holders — while 54 added to existing stakes and 38 trimmed.
The largest buyer was Avidity Partners Management, opening a new position worth an estimated $42.1M. The largest seller was Armistice Capital, cutting an estimated $101M.
- 188 institutional investors held Madrigal Pharmaceuticals (MDGL) as of Q4 2022, up from 135 in Q3 2022.
- Funds reported $3.86B of Madrigal Pharmaceuticals stock for Q4 2022, up 405% quarter-over-quarter.
- 80 funds opened new Madrigal Pharmaceuticals positions in Q4 2022 and 23 closed out, a net change of +57 holders.
- The largest Madrigal Pharmaceuticals buyer in Q4 2022 was Avidity Partners Management, an estimated $42.1M added.
- The largest Madrigal Pharmaceuticals seller in Q4 2022 was Armistice Capital, an estimated $101M sold.
Based on aggregated 13F filings for Q4 2022.